1. Baseline triglycerides and non-HDL-C and apoB goal attainment in the ORION-10 and ORION-11 trials. (25th November 2020) Authors: Ray, K.K; Kallend, D; Raal, F.J; Stoekenbroek, R; Koenig, W; Leiter, L.A; Landmesser, U; Schwartz, G.G; Wijngaard, P.L.J; Kastelein, J.J.P; Wright, R.S Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Inter-individual variability in LDL-C reductions with inclisiran – data from ORION-10 and ORION-11. (25th November 2020) Authors: Wright, R.S; Raal, F.J; Kallend, D; Stoekenbroek, R; Koenig, W; Leiter, L.A; Landmesser, U; Schwartz, G.G; Wijngaard, P.L.J; Kastelein, J.J.P; Ray, K.K Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11). (25th November 2020) Authors: Wright, R.S; Kallend, D; Raal, F.J; Stoekenbroek, R; Koenig, W; Leiter, L.A; Landmesser, U; Schwartz, G; Wijngaard, P.L.J; Kastelein, J.J.P; Ray, K.K Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗